R Squared Ltd Purchases New Position in Galapagos NV (NASDAQ:GLPG)

R Squared Ltd purchased a new stake in shares of Galapagos NV (NASDAQ:GLPG) during the 4th quarter, Holdings Channel.com reports. The institutional investor purchased 930 shares of the biotechnology company’s stock, valued at approximately $26,000.

Several other hedge funds and other institutional investors also recently modified their holdings of GLPG. Crossmark Global Holdings Inc. purchased a new position in shares of Galapagos during the third quarter valued at about $1,077,000. Creative Planning purchased a new stake in Galapagos in the second quarter worth about $456,000. Millennium Management LLC grew its holdings in Galapagos by 5.3% in the second quarter. Millennium Management LLC now owns 341,639 shares of the biotechnology company’s stock worth $8,466,000 after purchasing an additional 17,089 shares during the period. Finepoint Capital LP grew its holdings in Galapagos by 2.8% in the third quarter. Finepoint Capital LP now owns 557,762 shares of the biotechnology company’s stock worth $16,058,000 after purchasing an additional 15,000 shares during the period. Finally, Erste Asset Management GmbH purchased a new stake in Galapagos in the third quarter worth about $410,000. Hedge funds and other institutional investors own 32.46% of the company’s stock.

Wall Street Analyst Weigh In

GLPG has been the topic of a number of recent research reports. TD Cowen cut shares of Galapagos from a “strong-buy” rating to a “strong sell” rating in a report on Thursday, January 9th. Barclays restated an “underweight” rating on shares of Galapagos in a report on Thursday, January 23rd. Royal Bank of Canada cut their price objective on shares of Galapagos from $32.00 to $30.00 and set a “sector perform” rating on the stock in a report on Friday, November 1st. Finally, Kepler Capital Markets cut shares of Galapagos from a “hold” rating to a “reduce” rating in a report on Wednesday, November 20th. Four investment analysts have rated the stock with a sell rating and six have issued a hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $30.75.

Galapagos Trading Down 0.6 %

NASDAQ:GLPG opened at $22.69 on Wednesday. The company’s 50 day moving average price is $26.07 and its 200-day moving average price is $27.25. Galapagos NV has a 52 week low of $22.58 and a 52 week high of $40.34.

About Galapagos

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.